Comparison of the safety and efficacy of caroverine and betahistine in patients of subjective tinnitus
Keywords:
Caroverine, Betahistine, Subjective, Tinnitus, Tinnitus handicap inventoryAbstract
Background: Owing to lack of any established treatment and handicap assessment methods, subjective tinnitus can be a debilitating disorder. This study was carried out to compare the safety and efficacy of caroverine and betahistine in patients of subjective tinnitus.
Methods: A total of 60 patients of subjective tinnitus were randomized into two groups and followed-up for 12 weeks using tinnitus handicap inventory (THI) questionnaire. One group received 8 mg betahistine tablet TDS for a month whereas the other group was given supervised intravenous (IV) infusion of 160 mg of caroverine dihydrochloride. Data for the safety were also recorded.
Results: Both the drugs showed significant improvement in severity of symptoms at 1 week, 4 weeks and 12 weeks individually as assessed by the THI scores. The response to caroverine was significant up to 4 weeks, but it was not significant at 12 weeks; whereas the response to betahistine was significant up to 12 weeks. A total of 28 adverse drug reactions (ADRs) were reported (53.6% with caroverine, 46.4% with betahistine). 24 ADRs were mild and 4 were moderate in intensity. There was no serious adverse event.
Conclusions: Both the drugs are safe and efficacious in reducing the handicap of subjective tinnitus. A single IV infusion of caroverine may suffice for 4-6 weeks, so it may be repeated after 6 weeks to maintain the relief.
References
McFadden D. Tinnitus: facts, Theories and Treatments. Washington DC: National Academic Press; 1982.
Dhingra PL. Tinnitus. In: Diseases of Ear, Nose and Throat. 4th Edition. India: Elsevier; 2008: 126.
Adams PF, Hendershot GE, Marano MA. Current Estimates from the National Health Interview Survey. Vital and Health Statistics. Data from the National Health Survey. Series 10. Washington, D.C.: National Center for Health Statistics; 2000: 1-203.
Laurikainen EA, Miller JM, Quirk WS, Kallinen J, Ren T, Nuttall AL, et al. Betahistine-induced vascular effects in the rat cochlea. Am J Otol. 1993;14(1):24-30.
Henry JA, Schechter MA, Loovis CL, Zaugg TL, Kaelin C, Montero M. Clinical management of tinnitus using a “progressive intervention” approach. J Rehabil Res Dev. 2005;42 4 Suppl 2:95-116.
Zeman F, Koller M, Figueiredo R, Aazevedo A, Rates M, Coelho C, et al. Tinnitus handicap inventory for evaluating treatment effects: which changes are clinically relevant? Otolaryngol Head Neck Surg. 2011;145(2):282-7.
Newman CW, Sandridge SA, Jacobson GP. Psychometric adequacy of the tinnitus handicap inventory (THI) for evaluating treatment outcome. J Am Acad Audiol. 1998;9:153-60.
Available at http://www.earaudiology.com. Accessed 21 Sep 2012.
The use of the WHO-UMC system for standardized case causality assessment. Available at http://www.WHO-UMC.org/graphics/4409.pdf. Accessed 21 Sep 2013.
Cooper JC Jr. Health and Nutrition Examination Survey of 1971-75: part II. Tinnitus, subjective hearing loss, and well being. J Am Acad Audiol. 1994;5(1):37-43.
Nondahl DM, Cruickshanks KJ, Wiley TL, Klein R, Klein BE, Tweed TS. Prevalence and 5-year incidence of tinnitus among older adults: the epidemiology of hearing loss study. J Am Acad Audiol. 2002;13(6):323-31.
Eggermont JJ, Roberts LE. The neuroscience of tinnitus. Trends Neurosci, 2004;27(11):676-82.
Elgoyhen AB, Langguth B. Pharmacological approaches to the treatment of tinnitus. Drug Discov Today. 2010;15(7 8):300-5.
Ganança MM, Caovilla HH, Munhoz MS, Ganança CF, da Silva ML, Serafini F, et al. Optimizing the pharmacological component of integrated balance therapy. Braz J Otorhinolaryngol. 2007;73(1):12-8.
Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistine in the treatment of Ménière’s disease. Neuropsychiatr Dis Treat. 2007;3(4):429-40.
James AL, Burton MJ. Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev. 2001;(1):CD001873.
Denk DM, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol. 1997;117(6):825-30.
Domeisen H, Hotz MA, Häusler R. Caroverine in tinnitus treatment. Acta Otolaryngol. 1998;118(4):606-8.
Gananca MM, Munhoz MSL, Caovilla HH, Silva MLG. Managing vertigo. Hannover: Solvay; 2006: 112.
Petrova D, Sachansca T, Datcov E. Investigation of Betaserc in auditory and vestibular disturbances. Int Tinnitus J. 2004;10(2):177-82.
Ehrenberger K. Topical administration of Caroverine in somatic tinnitus treatment: proof-of-concept study. Int Tinnitus J. 2005;11(1):34-7.
